Multi-scale signaling and tumor evolution in high-grade gliomas

Proteome
DOI: 10.1016/j.ccell.2024.06.004 Publication Date: 2024-07-08T14:50:20Z
AUTHORS (261)
ABSTRACT
Although genomic anomalies in glioblastoma (GBM) have been well studied for over a decade, its 5-year survival rate remains lower than 5%. We seek to expand the molecular landscape of high-grade glioma, composed IDH-wildtype GBM and IDH-mutant grade 4 astrocytoma, by integrating proteomic, metabolomic, lipidomic, post-translational modifications (PTMs) with transcriptomic measurements uncover multi-scale regulatory interactions governing tumor development evolution. Applying 14 proteogenomic metabolomic platforms 228 tumors (212 16 astrocytoma), including 28 at recurrence, plus 18 normal brain samples metastases as comparators, reveals heterogeneous upstream alterations converging on common downstream events proteomic levels changes protein-protein glycosylation site occupancy recurrence. Recurrent genetic phosphorylation PTPN11 map important domains three dimensions, suggesting central role signaling across gliomas.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (124)
CITATIONS (14)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....